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ABSTRACT
Objectives: To re-evaluate the relation between plasma
interleukin-10 (IL-10) concentration at hospital admission
and outcome and to investigate the impact of single
nucleotide polymorphisms (SNP) in the IL-10 gene in
patients with non-ST elevation acute coronary syndrome
(ACS).
Design: Determination of IL-10 plasma concentrations
and genotyping of SNPs in the IL-10 gene in a prospective
trial of patients with ACS and in a group of healthy
controls.
Patients: 3179 patients in the Fragmin and fast
revascularisation during InStability in Coronary artery
disease II (FRISC II) trial and 393 healthy controls.
Main outcome measures: Mortality and incidence of
myocardial infarction (MI) at 12 months.
Results: The median and interquartile ranges of IL-10
were 0.8 (0.5–1.0) pg/ml in healthy controls and 1.1
(0.7–1.9) pg/ml in patients (p,0.001). In patients, IL-10
predicted a crude risk increase of death/MI, with the
highest risk observed in the fourth quartile (adjusted odds
ratio 1.7 (95% confidence interval 1.2 to 2.3)).
Adjustment for common risk indicators, including C-
reactive protein and interleukin-6, weakened the asso-
ciation to a non-significant level. The 1170 CC genotype
weakly predicted increased plasma concentrations of IL-
10 in patients (p=0.04) and in controls (p=0.03),
which was consistent with the modest association of this
variant with coronary disease (p=0.01).
Conclusion: In contrast with some previous reports, we
conclude that IL-10 reflects a proinflammatory state in
patients with ACS and we therefore suggest that IL-10 is
as effective a biomarker for the risk prediction of future
cardiovascular events as other markers of systemic
inflammation.
Acute coronary syndrome (ACS) is a clinical
manifestation of coronary atherosclerosis and
plaque disruption with superimposed thrombo-
sis.
12 Inflammation is a significant component
both in progression of atherosclerosis and in the
acute thrombotic event, as evidenced—for exam-
ple, by several studies associating proinflammatory
markers with subsequent coronary events.
34
Accumulating evidence also speaks for a role of
the immunoregulatory, anti-inflammatory cyto-
kine interleukin-10 (IL-10) in the aetiology of
ACS.
56 In vitro studies have demonstrated anti-
coagulant and anti-inflammatory properties of IL-
10, such as suppression of tissue factor expression,
cytokine production and interferon c synthesis by
activated monocytes/macrophages but also stimu-
latory effects such as B-cell growth and lipid
accumulation in oxLDL (low density lipoprotein)-
stimulated macrophages have been observed.
7–11 In
patients with ACS, low admission levels of IL-10 in
serum samples have been associated with an
increased risk of cardiovascular events and high
IL-10 levels with a decreased risk.
12–15 However,
conflicting results have also been published.
16
Therefore, the prognostic importance of IL-10 in
patients with ACS is not well understood and a
clinical consensus has not been reached.
Several reports describe associations between
genetic variants in the IL-10 gene and increased
secretion of IL-10 mRNA and protein.
17–20 Of those,
most studies have been restricted to the single
nucleotide polymorphisms (SNP) at positions
-1082 A.G, -819 C.T and -592 G.A in the
IL-10 gene.
The primary aim of the present study was to
compare plasma IL-10 concentrations in patients
with non-ST elevation ACS with those in healthy
subjects and to re-evaluate the relation between IL-
10 levels at hospital admission and future risk of
death and MI in patients. In addition, we
investigated whether SNPs in the IL-10 gene were




Non-ST elevation acute coronary syndrome
The patients in the present study participated in
the Scandinavian multicentre trial FRagmin and
fast revascularisation during InStability in
Coronary artery disease-II (FRISC-II), which com-
pared the benefits of an early invasive procedure
over a non-invasive strategy and a prolonged
treatment with a low-molecular weight heparin
(dalteparin) versus placebo.
21 22 Patients were eligi-
ble if they had symptoms of ischaemia that could
be verified by electrocardiography or increased
biochemical markers and if the last period of chest
pain had occurred within 48 hours from assign-
ment to open-label dalteparin (study randomisa-
tion). Patients with contraindications to early
revascularisation procedures or those included after
official study closure were enrolled in the non-
invasive arm only (n=1032). In total, 3489
patients were included in the trial and followed
regarding death and myocardial infarction (MI) for
12 months by an independent end point commit-
tee. The clinical end points were death, fatal or
non-fatal MI or the composite of those within a
follow-up time of 1 year.
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Apparently healthy individuals (n=393) who were similar in
age and gender to the FRISC-II patients were recruited from the
Swedish population registry.
23 The healthy subjects were
resident in southern, middle or northern parts of Sweden.
Only those without a clinical history of cardiovascular disease
or cardiovascular risk factors and with a normal electrocardio-
graphy and normal routine blood chemistry were eligible.
Compared with the patient group, individuals who smoked
were less frequent in the control group (14%). Written consent
was obtained from all study participants. These studies,
including the genetic substudy protocols, were approved by
the regional ethics review board of Uppsala and conform with
the principles outlined in the Declaration of Helsinki.
Early-onset myocardial infarction and matched healthy controls
The genetic associations observed in the FRISC-II cohort and
healthy control group were followed up in the SCARF study,
which included 362 survivors of MI and 381 age-matched and
sex-matched healthy controls from the same county as the
patients.
24 The SCARF database and biobank were generated for
studies of novel biochemical and molecular genetic markers of
MI. All SCARF participants were below the age of 60 and blood
sampling was performed 3 months after the index cardiac event.
All subjects gave their informed consent to participation. The
study was approved by the ethics committee at the Karolinska
University Hospital.
Laboratory analyses
Venous blood was drawn in citrated tubes (Vacutainer, Becton-
Dickinson) at admission to the coronary care unit of the
FRISC-II hospitals. Plasma was separated by centrifugation,
aliquoted and stored at –70uC until analysis. The median time-
lap between admission and blood sampling was 39 hours
(interquartile range 27–55) hours. High sensitive IL-10 was
measured using an ELISA technique with a lower detection limit
of 0.5 pg/ml (R&D Systems, Minneapolis, MN, USA). The
procedures for quantification of troponin-T (TnT), C-reactive
protein (CRP), interleukin-6 (IL-6) and B-type natriuretic
peptide (NT-proBNP) have been published.
25 26 Creatinine
clearance was estimated by the Cockrauft-Gault equation.
27
Plasma samples were available from 3179 FRISC-II participants
and DNA from 2951 patients.
SNP selection and genotyping
Seven tag SNPs within and flanking the IL-10 gene were selected
from the Seattle SNP database (fig 1).
28 Genotyping was
performed using the 12-plex GenomeLab SNPStream system
(Beckman Coulter) or the homogeneous template directed dye
terminator assay with fluorescence polarisation detection for
individual SNPs.
29 DNA was available from 2951 FRISC-II
patients and all healthy controls. The overall genotype call rate
was 95%, and the accuracy was 99.5% according to duplicate
analysis of on average, 14% of all genotypes (3996/28 306). The
IL-10 polymorphisms in all four subsets of patients and controls
were distributed according to the Hardy-Weinberg equilibrium.
The genotyping was performed by the SNP technology platform
at Uppsala University (www.medsci.uu.se/molmed/snpgeno-
typing).
Genotyping for the IL-10 1170 C.T SNP in the replication
study was performed using a pre-designed Taqman assay
(C___8828803_1_) (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Discrete data are presented as frequencies and percentages, and
continuous variables as medians and interquartile ranges.
Differences in levels of CRP and IL-10 between genotypes (or
other categorical variables) were tested using the Kruskal-Wallis
non-parametric test. Tests of independence for categorical
factors were performed using the x
2 distribution with two-
sided, exact p values. Logistic regression models were used to
estimate the associations between categorised plasma levels of
IL-10 and clinical end points. Regression model 1 adjusted for
age, sex, body mass index, smoking status, hypertension,
previous MI, diabetes, ST depression at entry, TnT .0.03 mg/l,
NT-pro-BNP, creatinine clearance, use of aspirin, angiotensin
converting enzyme (ACE)-inhibitor, b-blocker and statins.
Regression model 2 also included CRP, as a continuous variable,
and IL-6 plasma concentration above 5 ng/l. Statistics were
calculated in SPSS for Windows XP 13.0.
Figure 1 The IL-10 gene and the SNPs
genotyped in the present study. The SNPs
are indicated as position major.minor
allele shift. Open boxes represent exons
and shaded boxes represent untranslated
regions.
Figure 2 Box plot of IL-10 plasma concentrations in healthy controls
and patients with acute coronary syndrome.
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IL-10 plasma concentrations were significantly higher in the
patient group than in the healthy controls (fig 2). The number
of individuals with non-detectable IL-10 was 97 (24%) in the
control group and 531 (17%) in patients.
To investigate the impact of different time-laps before
sampling on IL-10 concentrations in patients, we compared
IL-10 concentrations over deciles of hours before sampling. No
statistically significant interaction between time before sam-
pling and IL-10 concentration was observed (p=0.72, Kruskal-
Wallis) (fig 3). In addition, the proportion of patients with
undetectable IL-10 was similar in patients with a short and long
period of time before sampling (p=0.21).
Baseline characteristics by interleukin-10 median level
The FRISC-II patients were stratified according to the median
IL-10 plasma concentration at admission. This analysis sug-
gested considerable differences in the baseline characteristics of
patients with IL-10 concentrations below and above median.
Conventional risk factors were more frequent among patients
with IL-10 concentrations above median, including elevation of
CRP and IL-6 but excluding previous MI and hypertension. In
contrast, smoking patients appeared to have a decreased IL-10
plasma secretion (table 1).
Interleukin-10 concentration at admission and risk of death and
myocardial infarction
The patients who were admitted with IL-10 concentrations in
quartile 1 were at a significantly lower risk of subsequent death
and MI compared with patients admitted with higher IL-10
concentrations (fig 4A and B). These trends were apparent in all
treatment groups, as indicated by interaction tests between
outcomes, IL-10 quartiles and treatment groups (data not
shown).
Since IL-10 plasma concentrations were correlated with other
risk factors, we investigated the predictive value of IL-10
quartiles using logistic regression models, which adjusted for
conventional risk indicators (see statistics section). After
adjustment, the risk of death in the highest IL-10 quartile
remained (adjusted odds ratio 2.6; 95% CI, 1.3 to 5.1)
(p=0.007) (table 2). Additional adjustment for CRP and IL-6
(model 2) changed the mortality risk associated with high IL-10
to a non-significant level (adjusted odds ratio, 1.7; 95%
confidence interval, 0.8 to 3.6) (p=0.13) (table 2). The risk of
MI associated with increased IL-10 was not significantly
elevated after adjustment for the risk indicators in model 1
(table 2). Additional adjustment for CRP and IL-6 did not
further alter this lack of association.
Association of the IL-10 1170 polymorphism with the acute
coronary syndrome and premature myocardial infarction
The 1170 C allele was significantly more common in FRISC-II
patients compared with the healthy control group (p=0.01).
None of the other SNPs were unequally distributed between
FRISC-II patients and controls (table 3). To further investigate
the relationship between 1170C.T and ACS we analysed this
SNP in a cohort of patients with early-onset MI together with
matched controls. However, the IL-10 1170 C.T SNP showed
no association with premature MI (T allele: 22% vs 21%,
p=0.72).
Comparison of 1170 C.T allele frequencies between patients
with and without a clinical end-point revealed no significant
difference in the FRISC-II patient group (p=0.09). After
adjustment for other risk indicators (model 2), a moderate
protective effect of the 1170 CT and TT genotypes was







Median age (IQR) 66 (58–73) 68 (60–75) ,0.001
Men/women 1058/544 1118/459 0.003
Current smokers 466 (29%) 375 (23%) ,0.001
BMI 26.4 (24.3–28.9) 26.3 (24.3–28.9) 0.92
Diabetes mellitus 176 (11%) 234 (15%) ,0.001
Hypertension 505 (32%) 530 (34%) 0.21
Previous MI 419 (26%) 444 (28%) 0.21
ST depression at admission 711 (44%) 781 50%) 0.009
CRP (mg/l) 4.6 (2.5–9.2) 10.6 (4.2–32.3) ,0.001
TnT >0.03 (mg/l) 1 005 (63%) 1 182 (75%) ,0.001
NT-pro-BNP >529 (ng/l) 422 (43%) 577 (57%) ,0.001
Creatinine clearance ,50 281 (18%) 381 (24%) ,0.001
IL-6 >5 (ng/l) 171 (10.8%) 1 182 (44%) ,0.001
IQR (interquartile range), CRP (C-reactive protein), TnT (troponin-T), NT-pro-BNP B-type natriuretic peptide, IL-6 (interleukin-6).
Figure 3 Hours between study randomisation and blood sampling.
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to 1.0) (p=0.036).
Associations between the IL-10 1170 C.T polymorphism and
plasma concentrations of interleukin-10 and C-reactive protein
The 1170 CC genotype was associated with approximately 20%
higher IL-10 plasma concentrations in both FRISC-II patients
and healthy controls (fig 5) (p=0.04, p=0.03 respectively). The
IL-10 -1082 A.G SNP were unassociated as were the other
polymorphisms genotyped in the present study. FRISC-II
patients with the 1170 CC genotype also exhibited increased
plasma levels of CRP (fig 5) (p=0.02). A trend towards
association with IL-10 plasma concentrations was observed in
patients with premature MI in the SCARF study (median,
interquartile range) (1170 CC: 1.5 (0.7–3.7), 1170 CT: 1.4 (0.8–
3.4) 1170 TT: 0.8 (0.4–1.4) (mg/l) (p=0.07).
DISCUSSION
The present study shows that patients with ACS have higher
IL-10 plasma concentrations than healthy controls and that
elevation of IL-10 on admission was associated with a large
number of common cardiovascular risk factors. In contrast to
previous studies, a high concentration of IL-10 on admission
was associated with a crude risk increase of death and MI. After
adjustment for several conventional risk indicators, including
markers for systemic inflammation, a clear association with
patient outcome was no longer evident.
Our primary results poorly support previous smaller reports
associating lower serum IL-10 levels with elevation of CRP,
unstable angina or an unfavourable prognosis in patients with
ACS.
12–15 Of note, our study consisted of 3634 individuals with
available plasma IL-10 determinations and is thus several-fold
larger than any previous study on this topic. Therefore, we also
had the possibility to investigate the distinct end-points of
death and MI separately, which we demonstrated were relevant
for the estimation of the predictive value of IL-10. Except for
clinical end-points, the discordant results between our and
previous studies may be attributable to differences in study
design, biochemical methods, patient cohorts, medications,
interventions and sampling time. Experimental studies have
indicated that sampling time may considerably influence IL-10
measurements; IL-10 production was delayed in a study of
patients measured before and after percutaneous coronary
intervention and in vitro the production of IL-10 in lipopoly-
sacharide-stimulated monocytes is delayed compared with that
of interleukin-1b, interleukin-8 (IL-8) and tumour necrosis
factor a (TNF- a).
30 31 As shown in figure 3, the influence of
hours before sampling on plasma IL-10 concentrations was low
for the different time intervals in our study. However, 98% of
the FRISC-II patients were sampled later than 8 hours after
study randomisation. Assuming that IL-10 concentrations are
initially high for patients exhibiting lower IL-10 later in the
acute course of events, a difference in the time lapsed before
blood sampling may still explain the discrepancy between ours
and a previous report on the prognostic value of IL-10 in ACS.
13
Our findings suggest that a majority of patients with ACS
present with considerably higher concentrations of IL-10 than
those observed in healthy individuals. The magnitude of IL-10
elevation in patients was correlated with the extent of systemic
Table 2 Odds ratios for patient outcomes according to IL-10 level at admission
IL-10
quartile
Univariate Model 1 Model 2
Percentage (no. of
events/total no.) OR (95% CI) p Value Adj OR (95% CI) p Value Adj OR (95% CI) p Value
Death 1 1.6% (13/805) Reference Reference Reference
2 3.4% (27/797) 1.9 (0.9 to 3.8) 0.080 1.6 (0.8 to 3.2) 0.234 1.4 (0.7 to 3.0) 0.35
3 4.7% (37/789) 2.7 (1.4 to 5.3) 0.004 1.8 (0.9 to 3.6) 0.105 1.5 (0.7 to 3.0) 0.30
4 6.1% (48/788) 3.4 (1.8 to 6.5) ,0.001 2.6 (1.3 to 5.1) 0.007 1.7 (0.8 to 3.6) 0.13
MI 1 8.3% (67/805) Reference Reference Reference
2 12.3% (98/797) 1.5 (1.1 to 2.2) 0.015 1.3 (0.9 to 1.9) 0.134 1.3 (0.9 to 1.9) 0.134
3 13.3% (105/789) 1.7 (1.2 to 2.4) 0.002 1.3 (0.9 to 1.9) 0.107 1.4 (1.0 to 1.9) 0.066
4 11.7% (92/788) 1.5 (1.0 to 2.1) 0.025 1.1 (0.8 to 1.6) 0.476 1.3 (0.9 to 1.9) 0.182
1 9.4% (76/805) Reference Reference Reference
Composite of
death/MI
2 14.3% (114/797) 1.5 (1.1 to 2.1) 0.011 1.3 (0.9 to 1.8) 0.130 1.3 (0.9 to 1.8) 0.172
3 16.0% (126/789) 1.8 (1.3 to 2.5) ,0.001 1.4 (1.0 to 1.9) 0.07 1.3 (1.0 to 1.9) 0.095
4 15.6% (123/788) 1.7 (1.2 to 2.3) 0.002 1.3 (0.9 to 1.8) 0.138 1.3 (0.9 to 1.8) 0.190
Model 1 adjusted for age, sex, BMI, previous MI, hypertension, diabetes, ST-depression at entry, dalteparin/placebo, TnT.0.03 mg/l, cholesterol .5.5 mM, smoking, creatinine
clearance, NT-pro-BNP, use of aspirin, ACE-inhibitor, b-blocker and statins. Model 2 included also CRP and IL-6.5 ng/l.
Table 3 Single nucleotide polymorphisms in the IL-10 gene
Minor allele frequency (%)





21082 A/G rs1800896 49.2 49.6 0.84
434 C/T rs2222202 49.3 49.0 0.86
1170 C/T rs1518111 25.9 21.8 0.01
1582 C/T rs1554286 21.7 19.2 0.07
1738 C/T rs3024507 1.8 2.0 0.78
2518 T/C rs3024509 6.0 6.4 0.60
3403 C/T rs3024495 15.8 14.1 0.17
4287 A/G rs3024498 27.0 26.9 0.95
*Tag SNP for IL-10 -819 C.T and -592 C.A.
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tions of CRP and IL-6, which may be a reflection of coronary
plaque rupture, thrombosis and cardiac damage. This observa-
tion leads to the notion that elevation of IL-10 is a consequence
of the increased inflammatory activity seen in ACS, which also
is related to long-term outcome.
The IL-10 gene is highly polymorphic and has been
extensively studied in relation to expression phenotypes and
association with human diseases. The 1170 C.T SNP is in
complete allelic association with several other variants in the IL-
10 gene, including the SNPs -592 C.A and -819 C.T, and was
selected to tag these genetic variants. The A allele of -592 C.A
and the T allele of -819 C.T have previously been linked to a
lower expression IL-10 mRNA.
18 Our results confirm that the
1170 C.T and linked polymorphisms, but not the -1082 G.A
or other SNPs in our study, are genetic markers of in vivo IL-10
production. However, the genetic effect of these variants on IL-
10 plasma concentrations was relatively small. The 1170 C.TC
allele was significantly more common in FRISC-II patients
compared to the age-matched and gender-matched healthy
control group. The association was not further established in
the replication study of young patients with early-onset MI,
which may indicate that other co-factors are necessary for this
variant to confer a risk increase. A weak association with
recurrent events in the FRISC-II study was also observed after
adjustment for cardiovascular risk factors. A recent report from
the large PROSPER study demonstrated a significant association
between a haplotype defined by the -592 C allele (in our study
represented by the 1170 C allele) and future risk of coronary
events, with an estimated hazard ratio of 1.2.
32 In summary, our
study and the PROSPER report suggest that the role of the IL-10
1170 C.T (and linked SNPs) in ACS is minor, which is also in
accordance with the small effect of 1170 C.T on plasma
concentrations of IL-10 and CRP.
The use of IL-10 as a biomarker for recurrent events in ACS is
complicated by the complexity of both timing and magnitude of
IL-10 secretion. Even so, our study showed that IL-10 plasma
concentrations at admission well reflect the presence of
common cardiovascular risk factors and can predict future
cardiovascular events. The strong association between elevation
of IL-10 and future events was significantly weakened only after
adjustment for CRP and IL-6, which suggests that IL-10 holds
Figure 4 Probability of death and myocardial infarction (MI) according
to IL-10 quartiles. (A) Kaplan-Meier estimate of the cumulative 12-month
probability of death. (B) Kaplan-Meier estimate of the 12-month
cumulative probability of MI.
Figure 5 Plasma concentrations of interleukin-10 and C-reactive
protein in patients and healthy controls according to 1170 C.T
genotypes. The box plot represents medians, interquartile ranges and
10th–90th percentiles. *p,0.05.
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inflammation. Therefore, IL-10 may prove at least as valuable
for risk prediction in ACS and can be considered as an
alternative to other systemic inflammatory markers.
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